Lieff Cabraser Civil Justice Blog
Lin Chan to Discuss Trends in Antitrust Class Actions at AAI 14th Annual Private Antitrust Enforcement Conference

Lin Chan to Discuss Trends in Antitrust Class Actions at AAI 14th Annual Private Antitrust Enforcement Conference

Lieff Cabraser partner Lin Y. Chan will speak at the American Antitrust Institute’s 14th Annual Private Antitrust Enforcement Conference on Tuesday, November 10th, 2020 at 1:00 p.m. Lin will be featured on the panel “The State of Private Enforcement: What 10-Year Trends Say About The Success of Antitrust Class Actions.”

Panelists will use the 2019 Antitrust Annual Report as a reference to discuss the major trends in antitrust class actions from 2009 to 2019 and their implications for private enforcement moving forward. A well-known resource for assessing the substance and importance of private enforcement in the U.S., the 2019 report takes a deep dive into the last decade of private antitrust class action lawsuits, from filing to case resolution.

The exceptional list of panelists includes:

Paul Bland, Jr., Executive Director, Public Justice

Lin Y. Chan, Partner, Lieff Cabraser Heimann & Bernstein, LLP

Joshua Davis, University of San Francisco Law School (Moderator)

Rose Kohles, Assistant Vice President, National Settlement Team, Huntington National Bank

For the full conference agenda visit the American Antitrust Institute website.

About Lin Chan

A partner in Lieff Cabraser’s San Francisco office, Ms. Chan has represented plaintiffs in employmentwhistleblower law, and antitrust cases. Her successes at the firm include representing direct purchasers of titanium dioxide against the titanium dioxide manufacturers for conspiring to fix prices. She worked extensively on the case’s trial preparation, including drafting and arguing motions in limine. In 2013, the case settled before trial for $163 million.

In 2017, Lin won the prestigious award for “Outstanding Antitrust Achievement by a Young Lawyer” from the American Antitrust Institute for her work on the Cipro drug antitrust cases, as well as sharing Lieff Cabraser’s team award from the AAI for “Outstanding Private Practice Antitrust Achievement” for their work on the Cipro case.